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 The present paper summarises the working methods and the findings of the multi-city 
study. 
Analysis of data suggests that a valuable assessment of drug misuse problems can be provided 
by drawing together findings from several indicators. It is essential that these agency-based 
data be complemented  by surveys and other studies of drug misuse in the population 
concerned. 
It has been put forward that a single organisational unit is needed with responsibility for 
integrating and analysing data from various agencies, research studies and other 
sources. 
Improvement in the consistency and quality of the data is to be fostered. The final report 
makes recommendations to that effect, inter alia with a view to possible future 
comparability between different European localities. 
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Background to the study 
 At the 6th Ministerial Conference of the Pompidou Group (November 1981) it was decided 
that “the development of administrative monitoring systems for the assessment of public health 
and social problems related to drug abuse” was one of the fields that should be given priority,^ As 
a consequence a meeting of epidemiology experts from different countries was convened in 
December 1982 to: 
− exchange views on epidemiological research in the field on non-medical use of drugs, 
− lay foundations for the pursuit and development of this exchange of Information and 
− develop proposals for international co-operation and future joint action. 
 The epidemiology research experts during their early meetings considered it useful for 
policy-makers and service-providers to be able to compare quantitatively and qualitatively the 
present situation and trends in drug problems of certain large cities. It was decided to carry out a 
comparative study on drug misuse in seven European cities: Amsterdam, Dublin, Hamburg, 
London, Paris, Rome and Stockholm. 
 The aim of the comparative study is to clarify indicators of drug misuse used in the 
different cities, to describe more clearly the extent of the problem taking into account differing 
cultural and policy contexts, and to Improve understanding and interpretation of such data within 
the Pompidou Group. 
 The epidemiology experts agreed that an approach based on cities was more feasible at this 
time than one comprising whole countries. Drug misuse patterns seen in one city often occur later 
in other European cities or may subsequently emerge on a national basis. Furthermore, drug 
misuse in large cities is acutely felt, and it is possible at a city level to take account of various 
important factors (socio-cultural, political, historical, etc) when interpreting the findings. At 
national level the situation is much more complex and can less readily be interpreted. 
The study employed the following design: 
1. review and summary of the data which are available on drug misuse in the seven cities; 
2. critical examination of the degree to which commonly used indicators, such as drug-related 
deaths or police arrests, are consistent and comparable between cities; 
3. assessment of the benefits and drawbacks of using these indicators to measure and interpret 
the extent and changing patterns of drug misuse; 
 
 
 
 
 
4. comparison of trends and prevalence between cities, to the extent that this is found feasible 
from the previous stages; 
5. consideration of what recommendations could be made in order to Improve comparability 
or elaboration of the indicators, 
The results of this study, completed in autumn 1986, are described in 2 sections. 
Section 1 of the final report: “Drug misuse in the seven cities: overview and 
city reports” 
 Section 1 contains the seven city reports (in standard format) together with an overview 
and synthesis of them. The following aspects of the drug misuse problem are discussed in the 
overview and synthesis: 
− legal framework: perspectives of control, 
− treatment, 
− information systems, 
− drug misuse; development and current situation, 
 It is shown that the ways in which the different societies have tried to cope with the 
problem have varied according to tradition, ideology, control policies and early experience with 
licit and illicit drug use. The emergence of illicit drug use as a significant social phenomenon in 
the 1960s seems to be common to all the cities. However, the development of drug misuse has 
occurred at different times and has taken on different forms, as concerns the population involved, 
the market situation and the availability of drugs. 
Section 2 of the final report: “The technical report on indicators of drug misuse” 
 This section not only examines the benefits, drawbacks and comparability of indicators 
used to assess and monitor drug misuse. It also puts forward, as a consequence of the analysis, 
proposals and recommendations for future epidemiological research. 
The indicators examined are: 
− First treatment demand, 
− Hospital admissions, 
− Viral hepatitis, 
− Drug-related deaths, 
− Police arrests, 
 
− Imprisonment, 
− Seizures of illicit drugs, 
− Price/purity of illicit drugs, 
− Survey data, 
− Other indicators. 
 In the appendix to section 2 data from the seven cities - population numbers and data from 
eight indicators of drug misuse - are presented as reference material for the technical report. The 
data were selected from the tables included in the individual city reports or were provided 
subsequently by the participating experts and have been presented according to a standardised 
format per indicator. The significance of the data shown in the appendix to section 2 and the 
extent to which they can be compared, vary according to the indicator concerned and the cities 
considered. 
It is shown that all indicators need improvement In terms of: 
− accessibility of the data, 
− rapidity with which the data can be obtained, 
− quality of the data with respect to reliability and validity, 
− consistency and comparability of the criteria. 
 Even though a low degree of direct comparability was found, it was possible to start to 
make rough comparisons between some cities at the levels of: 
− description, 
− trends in drug misuse, 
− profiles of drug users, 
− the relative significance of the drug misuse problem, 
− the prices of illicit drugs. 
 Despite the problems encountered, two indicators proved to be of particular value in most 
cities: first treatment demand and police arrests for offences involving illicit drugs. Certain other 
indicators could, after having been improved, add substantially to the range and quality of 
epidemiological information; drug-related deaths, drug seizures and prices, and hepatitis. Data on 
hospital admissions and imprisonment were considered to be of less epidemiological significance. 
 It was considered essential that the data derived from these agency-based indicators be 
complemented with findings from ethnographic studies, surveys and case-finding studies, etc. 
 
 The conceptual framework employed recognises that the drug-using population can be 
viewed as being composed of a group which is captured by various agency-based statistics and 
those as yet invisible to the agencies. Population-based surveys capture parts of both groups, 
while agency-based statistics reflect either the health or legal consequences of misuse, 
 The importance and interpretation of indicators are based on the understanding of two 
important factors which may affect their meaning; 
1. Each of the indicators is influenced by cultural attitudes and policies towards drug misuse. 
This may affect the probability of an individual being included in the system. 
2 Indicators, unlike surveys, are not direct measures of prevalence or even changes in 
prevalence. Despite the limitations of using any one indicator on its own, when taken 
together they provide a valuable assessment of drug misuse problems. Thus the 
convergence of findings from various indicators provides a more powerful and convincing 
case than a change in any single indicator. 
 Adherence to the above-mentioned principles will enable policy-makers to understand 
changes in the size and nature of the drug problem, identify populations at risk, plan intervention 
measures and evaluate the effect of these efforts. 
Conclusion 
 The most useful way of tying together information from different sources is central 
monitoring of data from various agencies. A major problem identified in most cities during this 
study was the lack of a structure for collecting and integrating data from very different sources in 
a consistent and coherent fashion. In each city there is an urgent need to improve and formalise 
the channels for pulling together information on a centralised, systematic and continuing basis. 
Once a data-base has been organised it will be easier to complement statistical data with 
qualitative, first-hand information from ethnographic studies of drug misuse in the communities 
and from case-finding and other studies. 
 It was felt that both statistical data and qualitative information are needed if the 
significance of data is to be shown. Multi-agency monitoring can, depending on the agencies 
Involved, provide information on trends in “known” prevalence and incidence, changes in the 
profiles of users, overlaps between different agencies and patterns of service utilisation. Apart 
from monitoring trends, the data formed in this way are of enormous value as a starting point for 
more thorough epidemiological evaluation of questions such as the long-term consequences of 
drug misuse. 
 
 
 
 
 
Proposals and recommendations for future work 
 Resulting from the findings in the city overview (Section l) and the technical report on 
indicators (Section 2) proposals have been put forward on two levels: city level and European 
level. 
City level 
At city level it is proposed that: 
A. Monitoring within cities will be improved by: 
1. establishing a centre, with sufficient resources, to collate information on a routine 
basis, both statistical data and more qualitative information, and with the 
“intelligence” needed to interpret the data; 
2. developing guidelines and protocols for collating and reporting data to the collation 
centre; 
3. developing a consistent format for producing reports of the results and a mechanism 
for disseminating the information to planners and services on a regular basis. 
B. Continuing attempts should be made to improve the quality of the Individual indicators as 
recommended in the technical report. 
 With regard to the establishment of a centre for data collection no specific blueprint is 
given. The starting point is the concept that information systems do not have to be identical; 
rather the inferences drawn from the different systems should be equivalent. Even though in some 
cities some elements of such a centre are present, the actual form will depend on the local 
context. Whether the centre is associated with the public health service, the criminal justice 
system, the local government structure, an interdepartmental arrangement or an independent 
institution, will depend on the historical and political traditions in each city. However, since the 
aim is to collate information on medical, legal and social aspects of drug misuse it may be 
preferable that the centre is not too closely identified with the interests of one particular section. 
European level 
 At European level improvement of the comparability and integration of data requires that 
there is an appropriate political-administrative structure to ensure that progress is made. Any 
attempt to monitor and compare the drug situation across Europe needs: 
− agreed guidelines on data gathering and 
− a continuing mechanism or forum for receiving, synthesising, interpreting and 
disseminating information. 
 
 
 
 Two possible ways of providing a framework for monitoring at European level have been 
described: 
A. The Pompidou Group institutionalises the epidemiology working party as the forum in 
which the experts meet every six months to: 
− present an update, in standard format, on national trends and 
− produce, with the other experts, a brief report that summarises the major trends and 
differences across Europe. 
Such a forum would facilitate the continuing exchange of information on epidemiological 
methods and results of new studies. 
B. Establishment of a European epidemiological centre to: 
− liaise with national centres, 
− define, in consultation with national centres, basic protocols for reporting data, 
− synthesise the information on a regular basis, 
− organise regular meetings to discuss the significance of the information and to identify 
future needs in the field, 
− disseminate briefings on the European situation to national centres and other relevant 
national/European bodies. 
 This second model is similar to the model proposed for monitoring in a city, but adapted to 
a multi-national European context. Such a centre would need full-time staffing. This model could 
be developed under the auspices of the Pompidou Group or it could be based elsewhere, 
 Either model aims to provide a common basis for the enhancement of understanding, 
methodological development, more informed discussion and decision-making, and mutual benefit 
from the experience of others. 
 It should be pointed out, however, that any move towards European co-ordination and 
comparability must take place in full consultation with other European bodies such as the 
European Communities and the European regional office of the World Health organisation, 
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